` MIRM (Mirum Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

MIRM
vs
S&P 500

Over the past 12 months, MIRM has outperformed S&P 500, delivering a return of +29% compared to the S&P 500's +14% growth.

Stocks Performance
MIRM vs S&P 500

Loading
MIRM
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
MIRM vs S&P 500

Loading
MIRM
S&P 500
Difference
www.alphaspread.com

Performance By Year
MIRM vs S&P 500

Loading
MIRM
S&P 500
Add Stock

Competitors Performance
Mirum Pharmaceuticals Inc vs Peers

S&P 500
MIRM
ABBV
CYTH
AMGN
GILD
Add Stock

Mirum Pharmaceuticals Inc
Glance View

Market Cap
2.6B USD
Industry
Biotechnology

In the competitive landscape of the biopharmaceutical industry, Mirum Pharmaceuticals Inc. has carved a niche for itself by specializing in rare liver diseases, a domain that requires both precision and dedication. Founded with a visionary goal, the company primarily focuses on developing treatments that address serious unmet needs within this sphere. At the heart of its operations is the development of maralixibat, a promising drug targeting progressive familial intrahepatic cholestasis and Alagille syndrome, which are both debilitating liver conditions affecting young patients. By addressing these niche markets, Mirum positions itself uniquely, translating complex science into tangible health outcomes. The company makes its money by navigating the rigorous path of drug development, from clinical trials to receiving regulatory approvals, ultimately transforming these therapies into marketable products. Mirum's business model is interlaced with the high stakes world of pharmaceuticals, where innovation meets exhaustive research and development. Revenue generation is contingent upon both the successful commercialization of its drug pipeline and strategic partnerships, which bolster their market reach and resource agility. By engaging closely with healthcare professionals and leveraging compassionate use and expanded access programs, they not only facilitate early adoption but also fuel the momentum needed for market penetration. Moreover, Mirum's commitment to education and engagement strategies fosters a robust ecosystem that underscores the importance of treating rare diseases. This way, the company not only sells its therapeutics but also creates enduring relationships within the medical community, significantly anchoring its financial and operational standing.

MIRM Intrinsic Value
44.18 USD
Overvaluation 15%
Intrinsic Value
Price
Back to Top